BeOne Medicines earnings release, August 5, 2026

BeOne Medicines Ltd. (ONC) · Form 8-K, Item 2.02 · Filed · SEC filing

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

• Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year

• BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year

• Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter

• Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion

SAN CARLOS, Calif. – August 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026.

John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:

“These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most diverse pipelines. With differentiated capabilities spanning drug discovery, clinical development, manufacturing, and commercialization, we are well positioned for our next phase of global growth.”

(Amounts in thousands of U.S. dollars and unaudited)

* For an explanation of our use of non-GAAP financial measures, refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.

Second Quarter 2026 Financial Results

Product Revenue totaled $1.7 billion for the second quarter of 2026, representing growth of 29% compared to the prior-year period.

• BRUKINSA: Global sales totaled $1.2 billion for the second quarter of 2026, representing growth of 31% compared to the prior-year period; U.S. sales of BRUKINSA totaled $893 million in the second quarter of 2026, representing growth of 31% compared to the prior-year period.

• TEVIMBRA (tislelizumab): Global sales totaled $229 million in the second quarter of 2026, representing growth of 18% compared to the prior-year period.

• Amgen in-licensed products: Global sales totaled $157 million in the second quarter of 2026, representing growth of 25% compared to the prior-year period.

Gross Margin as a percentage of global product sales for the second quarter of 2026 was 90%, compared to 87% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company’s portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA.

Operating Expenses

The following table summarizes operating expenses for the second quarter of 2026:

The following table summarizes operating expenses for the first half of 2026:

Research and Development (R&D) Expenses increased for the second quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to advancing early clinical programs into late stage and preclinical programs into the clinic. Upfront fees and milestone payments related to in-process R&D for in-licensed assets totaled $23.3 million and $0.5 million in the second quarter of 2026 and 2025, respectively.

Selling, General and Administrative (SG&A) Expenses increased for the second quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment to support commercial growth. SG&A expenses as a percentage of product sales were 35% for the second quarter of 2026, compared to 41% in the prior-year period.

Net Income and Basic/Diluted Earnings Per Share

GAAP net income for the second quarter of 2026 was $237 million, an increase of $143 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage. Adjusted net income was $444 million, an increase of $192 million over the prior-year period.

For the second quarter of 2026, basic and diluted earnings per share were both $0.16 per share and $2.12 and $2.05 per American Depositary Share (ADS), respectively, compared to basic and diluted earnings per share of $0.07 and $0.06 per share and $0.87 and $0.84 per ADS in the prior-year period. On an adjusted basis, basic and diluted earnings per share was $0.31 and $0.30 per share and $3.98 and $3.84 per ADS, respectively, compared to $0.18 and $0.17 per share and $2.33 and $2.25 per ADS in the prior-year period.

Free Cash Flow for the second quarter of 2026 was $435 million, representing an increase of $216 million over the prior-year period.

For further details on BeOne’s Second Quarter 2026 Financial Statements, please see BeOne’s Quarterly Report on Form 10-Q for the second quarter of 2026 filed with the U.S. Securities and Exchange Commission.

Updated Full Year 2026 Guidance

BeOne’s financial guidance is summarized below:¹

Assumes August 1, 2026 foreign exchange rates.²

Does not assume any potential new, material business development activity or unusual/non-recurring items.³

Non-GAAP operating income is a financial measure that excludes from the corresponding GAAP measure costs related to share-based compensation, depreciation and amortization expense. Guidance assumes that Non-GAAP expenses track overall expense growth.... (truncated)on a GAAP basis includes expectations of investment to support growth.

The Company is providing the following additional guidance on items impacting net income and earnings per ADS:

• Other income (expense):

Estimated range of $25 million to $50 million in expense, includes interest amortization from Royalty Pharma arrangement.

• Income tax outlook

: Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized; the timing and magnitude of a potential reversal is uncertain; prior to reversal, income tax expense should trend with earnings per historical relationship. See Form 10-Q for additional updates on income tax uncertainties.

• Diluted ADS outstanding:

The Company expects diluted ADSs outstanding of approximately 118 million.

Second Quarter 2026 Business Highlights

Core Marketed Products

BRUKINSA (zanubrutinib)

• Achieved positive topline results from the Phase 3 MANGROVE study in combination with rituximab demonstrating unprecedented progression-free survival (PFS) superiority versus bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma (MCL).

• Reported long-term 78-month follow-up data from the Phase 3 SEQUOIA study, which continue to demonstrate sustained PFS benefit for the treatment of adult patients with treatment-naïve chronic lymphocytic leukemia (CLL), at the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.

BEQALZI (sonrotoclax)

• Received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of adult patients with relapsed or refractory (R/R) MCL, after at least two lines of systemic therapy, including a BTK inhibitor.

TEVIMBRA (tislelizumab)

• Achieved Japan regulatory approval for the treatment of adult patients with first-line gastric cancer.

ZIIHERA (zanidatamab)

• Announced New England Journal of Medicine publication of full results from the Phase 3 HERIZON-GEA-01 study plus chemotherapy, with and without TEVIMBRA, versus trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA).

Select Clinical-Stage Programs

• Hosted an investor event at ASCO highlighting proof-of-concept data for three solid tumor programs, including BGB-43395 (CDK4 inhibitor), BGB-B2033 (GPC3x4-1BB bispecific antibody), and BG-C9074 (B7-H4 antibody-drug conjugate).

Hematology

• Tacabrutideg (BTK CDAC): Achieved last patient enrolled for Phase 3 CaDAnCe-303 (China-only) study (BGB-16673-303) in post-BTKi R/R CLL.

• BG-75202 (KAT6 A/B inhibitor): Achieved first patient enrolled into monotherapy cohort for Phase 1 study for the treatment of adult patients with acute myeloid leukemia.

Breast and Gynecological Cancers

• BGB-43395 (CDK4 inhibitor): Initiated Phase 3 study in combination with letrozole for the treatment of adult patients with first-line HR-positive, HER2-negative metastatic breast cancer.

Gastrointestinal Cancers

• BGB-58067 (MTA-cooperative PRMT5 inhibitor): Received U.S. FDA Orphan Drug Designation for the treatment of adult patients with pancreatic ductal adenocarcinoma.

Lung Cancer

• BON-110 (PD-1xVEGF-AxCTLA-4 trispecific antibody)

*

: Initiated first-in-human study.

Anticipated R&D Milestones

*

BeOne has entered into an exclusive option with Huahui Health to license worldwide rights to HH160 (BON-110), a novel trispecific antibody targeting PD-1, VEGF-A and CTLA-4.

Corporate Updates

• Announced a $300 million expansion of the Company’s flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, to add small molecule manufacturing capabilities.

• Appointed Felix J. Baker, Ph.D.; Elizabeth F. Mooney; and Charles L. Sawyers, M.D., to the Company’s Board of Directors.

BeOne’s Earnings Results Webcast

The Company’s earnings conference call for the second quarter 2026 will be broadcast via webcast at 8:00 a.m. ET on Wednesday, August 5, 2026, and will be accessible through the Investors section of BeOne’s website at www.beonemedicines.com. Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Financial statements

Income Statement

Three Months Ended — (Amounts in thousands of U.S. dollars and unaudited)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025% ChangeSix Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025% Change
Net product revenues1,679,7941,302,07629.0%3,167,1232,410,60631.0%
Other revenue25,27713,22491.0%51,38621,973134.0%
Total revenue1,705,0711,315,30030.0%3,218,5092,432,57932.0%
GAAP income from operations325,04787,885270.0%574,94998,987481.0%
Adjusted income from operations*503,029274,94583.0%917,423414,302121.0%
GAAP net income237,00794,320151.0%464,36495,590386.0%
Adjusted net income*444,497252,82276.0%819,539388,959111.0%
GAAP basic EPS per ADS2.120.87144.0%4.170.89369.0%
Adjusted basic EPS per ADS*3.982.3371.0%7.373.61104.0%
GAAP diluted EPS per ADS2.050.84144.0%4.010.85372.0%
Adjusted diluted EPS per ADS*3.842.2571.0%7.083.48103.0%
Free Cash Flow*435,344219,77298.0%595,891207,447187.0%

Income Statement

The following table summarizes operating expenses for the second quarter of 2026: (unaudited, in thousands, except percentages)

GAAP – Q2 2026GAAP – Q2 2025% ChangeNon-GAAP – Q2 2026Non-GAAP – Q2 2025% Change
Research and development612,280524,89617.0%533,950444,05720.0%
Selling, general and administrative593,214537,91310.0%500,674441,65513.0%
Total operating expenses1,205,4941,062,80913.0%1,034,624885,71217.0%

Income Statement

The following table summarizes operating expenses for the first half of 2026: (unaudited, in thousands, except percentages)

GAAP – Q2 YTD 2026GAAP – Q2 YTD 2025% ChangeNon-GAAP – Q2 YTD 2026Non-GAAP – Q2 YTD 2025% Change
Research and development1,153,5041,006,78315.0%999,854865,25216.0%
Selling, general and administrative1,148,311997,20115.0%972,667837,16616.0%
Total operating expenses2,301,8152,003,98415.0%1,972,5211,702,41816.0%

Income Statement

BeOne’s financial guidance is summarized below:

Prior FY 2026 GuidanceCurrent FY 2026 Guidance1
Total revenue$6.3B - $6.5B$6.6B - $6.8B
GAAP gross margin %High-80% rangeHigh-80% range
GAAP operating expenses2 (combined R&D and SG&A)$4.7B - $4.9B$4.8B - $5.0B
GAAP operating income2$750M - $850M$1.0B - $1.1B
Non-GAAP operating income2,3$1.45B - $1.55B$1.7B - $1.8B

Income Statement

Three Months Ended June 30, — (Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)

Three Months Ended June 30, – 2026 – (Unaudited)Three Months Ended June 30, – 2025 – (Unaudited)Six Months Ended June 30, – 2026 – (Unaudited)Six Months Ended June 30, – 2025 – (Unaudited)
RevenuesProduct revenue, net1,679,7941,302,0763,167,1232,410,606
RevenuesOther revenue25,27713,22451,38621,973
RevenuesTotal revenues1,705,0711,315,3003,218,5092,432,579
RevenuesCost of sales - products174,530164,606341,745329,608
RevenuesGross profit1,530,5411,150,6942,876,7642,102,971
Operating expenses:Research and development612,280524,8961,153,5041,006,783
Operating expenses:Selling, general and administrative593,214537,9131,148,311997,201
Operating expenses:Total operating expenses1,205,4941,062,8092,301,8152,003,984
Operating expenses:Income from operations325,04787,885574,94998,987
Operating expenses:Interest income27,90011,49255,56424,342
Operating expenses:Interest expense-39,739-7,995-72,626-14,997
Operating expenses:Other (expense) income, net-7498,16713,78712,117
Operating expenses:Income before income taxes312,45999,549571,674120,449
Operating expenses:Income tax expense75,4525,229107,31024,859
Operating expenses:Net income237,00794,320464,36495,590
Earnings per shareBasic0.160.070.320.07
Earnings per shareDiluted0.160.060.310.07
Earnings per shareWeighted-average shares outstanding—basic1,450,485,5521,408,166,7541,446,490,9041,399,159,898
Earnings per shareWeighted-average shares outstanding—diluted1,505,361,9001,463,277,4011,505,389,1821,454,296,475
Earnings per American Depositary Share (“ADS”)Basic2.120.874.170.89
Earnings per American Depositary Share (“ADS”)Diluted2.050.844.010.85
Earnings per American Depositary Share (“ADS”)Weighted-average ADSs outstanding—basic111,575,812108,320,520111,268,531107,627,684
Earnings per American Depositary Share (“ADS”)Weighted-average ADSs outstanding—diluted115,797,069112,559,800115,799,168111,868,960

Income Statement

Three Months Ended — (unaudited)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Reconciliation of GAAP to adjusted cost of sales - products:GAAP cost of sales - products174,530164,606341,745329,608
Reconciliation of GAAP to adjusted cost of sales - products:Less: Depreciation5,5203,3219,8465,934
Reconciliation of GAAP to adjusted cost of sales - products:Less: Amortization of intangibles1,5925,7493,3346,922
Reconciliation of GAAP to adjusted cost of sales - products:Less: Other893893
Reconciliation of GAAP to adjusted cost of sales - products:Adjusted cost of sales - products167,418154,643328,565315,859

Income Statement

Three Months Ended — (unaudited)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Reconciliation of GAAP to adjusted net income:GAAP net income237,00794,320464,36495,590
Reconciliation of GAAP to adjusted net income:Plus: Share-based compensation expenses137,467150,553260,815246,004
Reconciliation of GAAP to adjusted net income:Plus: Depreciation38,90629,85478,29161,468
Reconciliation of GAAP to adjusted net income:Plus: Amortization of intangibles1,6095,7603,3686,950
Reconciliation of GAAP to adjusted net income:Plus: Other893893
Reconciliation of GAAP to adjusted net income:Plus: Impairment of equity investments3,11815,494
Reconciliation of GAAP to adjusted net income:Plus: Discrete tax items49,839-14,21053,374-8,737
Reconciliation of GAAP to adjusted net income:Plus: Income tax effect of non-GAAP adjustments1-20,331-17,466-40,673-28,703
Reconciliation of GAAP to adjusted net income:Adjusted net income444,497252,822819,539388,959
Reconciliation of GAAP to adjusted EPS - basicGAAP earnings per share - basic0.160.070.320.07
Reconciliation of GAAP to adjusted EPS - basicPlus: Share-based compensation expenses0.090.110.180.18
Reconciliation of GAAP to adjusted EPS - basicPlus: Depreciation0.030.020.050.04
Reconciliation of GAAP to adjusted EPS - basicPlus: Amortization of intangibles0000
Reconciliation of GAAP to adjusted EPS - basicPlus: Other0000
Reconciliation of GAAP to adjusted EPS - basicPlus: Impairment of equity investments0000.01
Reconciliation of GAAP to adjusted EPS - basicPlus: Discrete tax items0.03-0.010.04-0.01
Reconciliation of GAAP to adjusted EPS - basicPlus: Income tax effect of non-GAAP adjustments1-0.01-0.01-0.03-0.02
Reconciliation of GAAP to adjusted EPS - basicAdjusted earnings per share - basic0.310.180.570.28
Reconciliation of GAAP to adjusted EPS - dilutedGAAP earnings per share - diluted0.160.060.310.07
Reconciliation of GAAP to adjusted EPS - dilutedPlus: Share-based compensation expenses0.090.10.170.17
Reconciliation of GAAP to adjusted EPS - dilutedPlus: Depreciation0.030.020.050.04
Reconciliation of GAAP to adjusted EPS - dilutedPlus: Amortization of intangibles0000
Reconciliation of GAAP to adjusted EPS - dilutedPlus: Other0000
Reconciliation of GAAP to adjusted EPS - dilutedPlus: Impairment of equity investments0000.01
Reconciliation of GAAP to adjusted EPS - dilutedPlus: Discrete tax items0.03-0.010.04-0.01

Income Statement

(Unaudited)(Unaudited)
Operating Income Guidance for Full Year 2026GAAP operating income1,000,0001,100,000
Operating Income Guidance for Full Year 2026Plus: Adjustments to arrive at Non-GAAP1700,000700,000
Operating Income Guidance for Full Year 2026Non-GAAP operating income1,700,0001,800,000

Balance Sheet

(Amounts in thousands of U.S. Dollars)

As of – June 30, – 2026 – (unaudited)As of – December 31, – 2025 – (audited)
Assets:Cash, cash equivalents and restricted cash5,280,6744,609,647
Assets:Accounts receivable, net1,056,177865,080
Assets:Inventories732,603608,227
Assets:Property, plant and equipment, net1,643,2861,641,678
Assets:Total assets9,175,6158,188,573
Liabilities and equity:Accounts payable470,299479,035
Liabilities and equity:Accrued expenses and other payables1,264,2641,109,120
Liabilities and equity:R&D cost share liability6,18264,345
Liabilities and equity:Sale of future royalty liability906,313906,956
Liabilities and equity:Debt1,073,0591,019,206
Liabilities and equity:Total liabilities4,001,6173,827,379
Liabilities and equity:Total equity5,173,9984,361,194

Cash Flow

Three Months Ended June 30, — (Amounts in thousands of U.S. Dollars)

Three Months Ended June 30, – 2026 – (unaudited)Three Months Ended June 30, – 2025 – (unaudited)Six Months Ended June 30, – 2026 – (unaudited)Six Months Ended June 30, – 2025 – (unaudited)
Cash, cash equivalents and restricted cash at beginning of period4,853,4252,530,5914,609,6472,638,747
Net cash provided by operating activities462,820263,598664,156307,680
Net cash used in investing activities-49,353-66,605-94,863-188,546
Net cash (used in) provided by financing activities-6,05435,02562,5781,248
Net effect of foreign exchange rate changes19,83623,47739,15626,957
Net increase in cash, cash equivalents, and restricted cash427,249255,495671,027147,339
Cash, cash equivalents and restricted cash at end of period5,280,6742,786,0865,280,6742,786,086

Cash Flow

Three Months Ended

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Free Cash Flow (Non-GAAP):Net cash provided by operating activities (GAAP)462,820263,598664,156307,680
Free Cash Flow (Non-GAAP):Less: Purchases of property, plant and equipment-27,476-43,826-68,265-100,233
Free Cash Flow (Non-GAAP):Free Cash Flow (Non-GAAP)435,344219,772595,891207,447
Full release

Forward-Looking Statements... (truncated) of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

Condensed Consolidated Statements of Operations (U.S. GAAP)

(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)

Select Condensed Consolidated Balance Sheet Data (U.S. GAAP)

(Amounts in thousands of U.S. Dollars)

Select Condensed Consolidated Statements of Cash Flows (U.S. GAAP)

(Amounts in thousands of U.S. Dollars)

Note Regarding Use of Non-GAAP Financial Measures

BeOne provides certain non-GAAP financial measures, including Adjusted Operating Expenses, Adjusted Operating Loss, Adjusted Net Income, Adjusted Earnings Per Share, Free Cash Flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne’s operating performance. Adjustments to BeOne’s GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne’s operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne’s management uses for planning and forecasting purposes and measuring BeOne’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES

(Amounts in thousands of U.S. Dollars, except for per share and per ADS data)

(unaudited)

1.

Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the relevant tax jurisdiction. Please note that the Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects.

1.

The non-GAAP adjustments are based on best available information at this time related to non-cash items similar to those reported in our actual Non-GAAP results.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · BeOne Medicines earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.